BMI differences for clinical outcome in patients with advanced or metastatic gastric cancer treated with apatinib: Data from a post-marketing phase IV study (Ahead-G201)

Authors :: Likun Liu
Yuxian Bai
Zhong Xie
Mei Wang
Junsheng Wang
Wenying Deng
Yifu He
Tongfu Jia
Shukui Qin
Guifang Zhang
Feng Ye
Xiaoyan Lin
Lu Wen
Xiang-Yuan Wu
Tienan Yi
Jin Li
Haijun Zhong
Yong Huang
Yi Ba
Jianwei Yang
Source :: Journal of Clinical Oncology. 36:e16027-e16027
Publication Year :: 2018
Publisher :: American Society of Clinical Oncology (ASCO), 2018.
Abstract: e16027Background: Studies have shown BMI could affect long-term survival in advanced gastric cancer. In this analysis, based on a large population, we further investigated the effects of BMI on the...

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
business.industry
Large population
nutritional and metabolic diseases
Advanced gastric cancer
Affect (psychology)
Metastatic gastric cancer
chemistry.chemical_compound
chemistry
Internal medicine
medicine
Apatinib
In patient
business

Full Text Access

Tools